hVIVO €3.2m contract for Venn Life Sciences with global pharmaceutical client

hVIVO plc

hVIVO plc (Euronext & LON:HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its consultancy services division, Venn Life Sciences, has signed a contract with a major global pharmaceutical client worth €3.2m over two years.

The contract commences in January 2023, with the Venn team in Breda providing dedicated complex clinical pharmacokinetics consultancy and programming services to this global pharmaceutical client on a number of drug development programmes across multiple therapeutic areas, to study the absorption, distribution and excretion of drugs within the body.

Venn has nearly 30 experts dedicated to providing PK and programming services to clients and has been a trusted partner to the pharma industry for over 25 years. These services cover a diverse range of trials and therapeutic areas ranging from traditional phase I trials to more complex and challenging trials, such as oncology and ATMP (Advanced Therapy Medicinal Product) trials. Venn is a leader in providing fully integrated drug development services from early drug discovery to clinical trials. Its offering includes drug development consultancy, clinical trial design and execution services with expertise and capabilities in CMC (Chemistry, Manufacturing and Controls), Non-Clinical, Clinical Pharmacology and Development, Statistics, Study Design and Methodology, Data Management, Medical Writing and Regulatory Affairs. These combined services enable Venn to provide its clients with a complete end-to-end service on all stages of their drug development programmes, from the early planning phase to final execution. Venn has offices in Breda (Netherlands) and Paris (France).

Yamin ‘Mo’ Khan, Chief Executive Officer of hVIVO, said: “The consultancy work included in this two-year contract highlights the continued expansion of our pharmacokinetic and programming services as part of Venn’s integrated drug development services provision. Venn’s outstanding expertise and reputation in the industry over the past 25 years makes them a go-to partner. In addition, for infectious disease products, hVIVO and Venn have also been able to conduct projects from discovery to Phase II Challenge Studies, something no one else can offer.”

Dr Katsuhiro Mihara, Head of Clinical Development of Venn Life Sciences, commented: “This contract is a great example of Venn’s ability to deliver on long term PK and programming projects. We have worked closely with hVIVO to identify ways to leverage this strong client base, to drive both upselling and cross-selling opportunities, and find even greater synergies between the two integrated clinical services businesses.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:
hVIVO plc (LON:HVO), a leader in human challenge clinical trials, will announce its 2024 results on April 10, 2025, with an analyst briefing to follow.
hVIVO plc, a leader in human challenge clinical trials, has acquired Cryo-Store Limited to enhance its biobank and laboratory services with advanced storage solutions.
hVIVO plc secures a £2 million contract post-successful hMPV trial, advancing critical human challenge studies for future vaccine development.
hVIVO plc, a leader in human challenge clinical trials, reports successful Phase 2a results for Shionogi's RSV antiviral, S-337395, showing significant efficacy.
hVIVO plc partners with Inhalon Biopharma to test IN-002, an inhaled antiviral for RSV, in a Phase 2a trial using their RSV Human Challenge Model.
hVIVO expands its clinical footprint by acquiring CRS, a German CRO, adding Phase I & II trial capabilities in Europe, enhancing strategic growth for 2025-2026.

Search

Search